Loading
Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease.
Ramez Eskander was principal investigator of NRG-GY018 (KEYNOTE-868), which showed adding pembrolizumab to carboplatin-paclitaxel improves progression-free survival in advanced or recurrent endometrial cancer in both mismatch repair-deficient and proficient populations, published alongside RUBY to establish chemo-immunotherapy as first-line standard. He leads gynaecologic oncology trials at UC San Diego and within NRG Oncology.
| Title | Journal | Year |
|---|---|---|
| Pembrolizumab plus chemotherapy in advanced endometrial cancer (NRG-GY018) | NEJM | 2023 |
| Pembrolizumab plus chemotherapy in advanced endometrial cancer: overall survival and progression-free survival by mismatch repair status | JCO | 2025 |
Shares UC San Diego Moores Cancer Center, PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Endometrial cancer, PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares GOG Foundation, Endometrial cancer.
Shares Endometrial cancer and the tags endometrial, immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.